EileenLagathu

Of Counsel

Paris + 33.1.56.59.39.32

Plus de 10 ans de pratique ont permis à Eileen Lagathu d’acquérir une expérience significative des différentes facettes du droit de la concurrence européen et français, tant en matière de contrôle des concentrations que d’aides d’Etat et d’enquêtes pour cartels de la Commission européenne ou de l’Autorité de la concurrence. Elle a également représenté des clients dans de nombreux contentieux devant le Tribunal et la Cour de Justice de l’UE, ainsi que devant la Cour d’appel de Paris, dans des affaires emblématiques, qui ont contribué à façonner la jurisprudence relative aux amendes.

Eileen Lagathu accompagne quotidiennement les clients dans l’élaboration de leurs contrats commerciaux, notamment des accords de R&D ou d’exclusivité, et plus généralement, dans la structuration de leurs réseaux de distribution. Elle les aide également à mettre en place des mesures de conformité. Elle conseille également des multinationales sur les questions de contrôle des concentrations soulevées par leurs transactions (cessions d’actifs, de titres, créations de JV). Elle travaille régulièrement sur des notifications à la Commission européenne ou à l’Autorité de la concurrence, et la coordination de notifications multi-juridictionnelles.

Elle représente régulièrement des clients dans les secteurs énergétique, pharmaceutique, bancaire et financier, ce qui lui a permis d’acquérir une compréhension approfondie de ces domaines.

Eileen Lagathu a une connaissance particulièrement développée en matière d’amendes, en sa qualité de co-auteur, depuis 2013, de l’étude annuelle : Law on Fines Imposed in EU Competition Proceedings, publiée par la revue JECLAP (Oxford Academic).

Expérience

  • Tender offer for Eurobio Scientific launched by NextStage AM and IK PartnersJones Day is advising Eurobio Scientific SA in the tender offer launched by a consortium led by the management of Eurobio Scientific and funds managed by NextStage AM and IK Investment Partners, at a price of €25.3 per share increased by €1.25 per share if the threshold of 90% of Eurobio Scientific's capital and voting rights is reached, representing a maximum amount of approximately €161 million and valuating Eurobio Scientific at approximately €270 million.
  • Amolyt Pharma acquired by AstraZenecaJones Day advised Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in developing therapeutic peptides for rare endocrine and related diseases, in its $1.05 billion acquisition by AstraZeneca.
  • Silver Lake Waterman, Eurazeo, Partech Partners, Eight Roads, F-Prime, and Serena Capital participate in $54 million Series C financing of OdasevaJones Day advised Silver Lake Waterman, the lead new investor, and Eurazeo, a new investor, as well as historical investors Partech Partners, Eight Roads, F-Prime and Serena Capital in connection with the $54 million Series C financing of Odaseva, the leading enterprise data security platform for Salesforce, along with new investor Crescent Cove.
  • Société Générale sells Société Générale Equipment Finance's (SGEF) activitiesJones Day is advising Société Générale in the sale of the professional equipment financing businesses operated by Societe Generale Equipment Finance (SGEF) to Groupe BPCE.
  • Kartesia sells shares in Orapi to Groupe ParedesJones Day advised Kartesia Management SA in the sale of the shares held in Orapi SA to Groupe Paredes as part of Groupe Parades' public tender offer for Orapi SA.
  • Silicon Mobility sold to IntelJones Day advised Silicon Mobility SAS in the acquisition of the company by Intel Corporation.
  • Cellectis and AstraZeneca enter into research collaboration and agree on equity investment of up to $220 million by AstraZenecaJones Day advised Cellectis in connection with the joint research collaboration agreement entered into with AstraZeneca and initial equity investment by AstraZeneca into Cellectis of $80 million.
  • Sanofi sells portfolio of well-established consumer healthcare brands to STADAJones Day advised Sanofi in the sale of a portfolio of 7 well-established consumer healthcare brands across several countries, including Belgium, Germany, Hungary, Spain, the U.K., as well as Nordic countries, to STADA Arzneimittel AG.
  • TotalEnergies fully acquires Total Eren after a successful strategic alliance of five yearsJones Day acted as Antitrust counsel to TotalEnergies in its buyout of Total Eren's other shareholders, increasing its stake from close to 30% to 100% after a successful strategic alliance of five years.
  • Orano and XTC New Energy create two JVs dedicated to the production of batteries for electric vehiclesJones Day is advising Orano in the context of the setting-up of two joint-ventures dedicated to the production of critical materials for batteries for electric vehicles, together with Chinese group XTC New Energy.
  • TotalEnergies' affiliate Cray Valley sells three product lines to Pacific Avenue Capital PartnersJones Day is advising Total Energies on its sale of three product lines to Pacific Avenue Capital Partners (Wingtack®, PolyBD® and Dymalink®) developed by Cray Valley, its resin production and sales affiliate.
  • Sanofi sells two established product portfolios to NeuraxpharmJones Day advised Sanofi in the sale of 2 portfolios of products for central nervous systems disorders and pain and vascular diseases to LESVI, a Spanish subsidiary of Neuraxpharm.
  • Swile and Groupe BPCE to combine to create global leader in employee benefitsJones Day advised Swile, a worktech unicorn, in the acquisition of Bimpli, a subsidiary of Groupe BPCE and leader in employee services and benefits in France.
  • Ansys acquires automotive simulation channel partner DYNAmoreJones Day is representing Ansys, Inc. in the acquisition of the DYNAmore business (“DYNAmore”), a Stuttgart, Germany-headquartered company who has historically distributed Ansys’ LS-DYNA crash test simulation software to virtually all major European car manufacturers.
  • Sanofi divests IMOJEV® to SUBSTIPHARMJones Day advised Sanofi in the sale of the Japanese Encephalitis vaccine IMOJEV® to SUBSTIPHARM, a privately held pharmaceutical group.
  • Sanofi sells anti-infective portfolio to ADVANZ PHARMAJones Day advised Sanofi in the sale of a portfolio made up of eight anti-infectives including Azactam™, Cefotax™, Claforan™, Oroken™, Rulid™, Suprax™, Wintriaxone™ and Colistimethate Sodique products, which are critical in treating a broad range of infections, to ADVANZ PHARMA Corp. Limited, a UK-headquartered global pharmaceutical company with a strategic focus on specialty and hospital pharmaceuticals.
  • Deezer merges with and into I2PO S.A.Jones Day advised Deezer S.A. in the context of the SPAC transaction whereby Deezer S.A. merged with and into I2PO S.A., a French SPAC listed on the professional segment of the regulated market of Euronext Paris and the related PIPE financing.
  • Sanofi announces carve-out creating EUROAPI and spin-off of approximately 58% of shares to its shareholdersJones Day advised Sanofi in the carve out creating EUROAPI (a leading European company dedicated to the development, production and marketing of active pharmaceutical ingredients) and the listing of this entity on Euronext Paris and the placement of 12% to the French State (through French Tech Souveraineté) for a price of up to €150 million.
  • Simpson Manufacturing Company announces offer to acquire Etanco GroupJones Day advised Simpson Manufacturing Company, Inc. in the €725 million acquisition of the Etanco Group.
  • Sanofi sells 10 established products to CheplapharmJones Day advised Sanofi in the sale of a portfolio of pharmaceutical products to Cheplapharm Arzneimittel GmbH, a German privately-owned company headquartered in Greifswald, Germany.